AbbVie adds John M. Carethers to board, expanding to 13 directors
AbbVie appointed Dr. John M. Carethers as a Class II director on October 14, 2026, according to an 8-K filed with the SEC.
AbbVie Inc. disclosed in a Form 8-K that on October 14, 2026, it expanded the size of its Board of Directors from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director.1
According to the filing, Dr. Carethers holds the role of Vice Chancellor for Health Sciences at the University of California San Diego and had earlier served on the board of Avantor, Inc.1 The filing also states he has joined AbbVie's Public Policy and Sustainability Committee.
AbbVie's board determined that Dr. Carethers qualifies as an independent director, citing compliance with the independence standards under section 303A.02 of the New York Stock Exchange Listed Company Manual as well as AbbVie's own governance and director independence guidelines.1
The filing notes that his pay as an independent director will follow the terms already laid out in a prior compensation exhibit, specifically the arrangement disclosed in Exhibit 10.5 of AbbVie's quarterly report on Form 10-Q for the period ended March 31, 2025.1
The 8-K was signed on October 15, 2026, by Perry C. Siatis, AbbVie's Executive Vice President, General Counsel and Secretary.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.